Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT02093962 | Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 265 | ImmunoGenesisINDUSTRY | 10 | May 16, 2025 |
| clinicaltrials |
| NCT04171219 | Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers | terminated | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 8 | Novartis PharmaceuticalsINDUSTRY | 3 | May 16, 2025 | clinicaltrials |
| NCT04926181 | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | terminated | Phase 2 | 2 | Rahul AggarwalOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05972720 | A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma(FIRCE-1) | terminated | Phase 2 | 101 | CARGO TherapeuticsINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT02521051 | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 11 | Massachusetts General HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04556084 | Blinatumomab Bridging Therapy for BALL | terminated | Phase 2 | 2 | Michael BurkeOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04965311 | Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy | terminated | Phase 2 | 4 | OHSU Knight Cancer InstituteOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01864538 | A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | terminated | Phase 2 | 11 | ImmunoGenesisINDUSTRY | 2 | May 11, 2025 | clinicaltrials |
| NCT04633278 | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 2 | 24 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT05311176 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)(nextHERIZON) | terminated | Phase 2 | 7 | Imugene LimitedINDUSTRY | 2 | May 11, 2025 | clinicaltrials |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma(SIRCCA) | terminated | Phase 2 / Phase 3 | 89 | Sirtex MedicalINDUSTRY | 8 | May 9, 2025 | clinicaltrials |
| NCT03456700 | Auranofin and Sirolimus in Treating Participants With Ovarian Cancer | terminated | Phase 2 | 22 | Mayo ClinicOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04827576 | Study of Magrolimab in Patients With Solid Tumors(ELEVATELung&UC) | terminated | Phase 2 | 106 | Gilead SciencesINDUSTRY | 5 | May 8, 2025 | clinicaltrials |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 16 | Coherus Oncology, Inc.INDUSTRY | 2 | May 8, 2025 | clinicaltrials |
| NCT01834235 | QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 81 | Precision Biologics, IncINDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT01550510 | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | terminated | Phase 1 / Phase 2 | 4 | Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 28 | Helix BioPharma CorporationINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT04853043 | Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer(APK Mutant) | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05251233 | Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy | terminated | Phase 2 | 56 | Washington University School of MedicineOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT01555489 | Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | terminated | Phase 2 | 11 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02569957 | Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | terminated | Phase 2 | 1 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT05388435 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | terminated | Phase 1 / Phase 2 | 15 | SK Life Science, Inc.INDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT04217317 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma | terminated | Phase 2 | 6 | Wake Forest University Health SciencesOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 36 | Gilead SciencesINDUSTRY | 3 | May 2, 2025 | clinicaltrials |
| NCT01313559 | Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer | terminated | Phase 2 | 6 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03660930 | Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | terminated | Phase 1 / Phase 2 | 19 | University of WashingtonOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06003075 | Induction Chemo-Nivo in Unresectable Stage III NSCLC | terminated | Phase 2 | 1 | Ralph G ZinnerOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT04483544 | Pembrolizumab and Olaparib in Cervical Cancer Patients | terminated | Phase 2 | 8 | Baptist Health South FloridaOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT00238355 | Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems | terminated | Phase 2 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT02122172 | Afatinib in Advanced Refractory Urothelial Cancer | terminated | Phase 2 | 32 | University of ChicagoOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT00848328 | Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma | terminated | Phase 2 | 30 | University of California, DavisOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 376 | Bristol-Myers SquibbINDUSTRY | 17 | Apr 24, 2025 | clinicaltrials |
| NCT05275673 | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 7 | Faeth TherapeuticsINDUSTRY | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06941688 | Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma | terminated | Phase 2 | 17 | Seoul National University HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging | terminated | Phase 1 / Phase 2 | 7 | Stanford UniversityOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04892472 | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer(KEYNOTE B36) | terminated | Phase 2 | 15 | NovoCure GmbHINDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | terminated | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 2 | Apr 22, 2025 | clinicaltrials |
| NCT04047797 | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma(ABE-LIVER) | terminated | Phase 2 | 3 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT04006119 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 40 | Alaunos TherapeuticsINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04294277 | Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery(PEGASUS) | terminated | Phase 2 | 2 | European Association of Urology Research FoundationOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04925986 | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | terminated | Phase 2 | 9 | Sarah GoldbergOTHER | 1 | Apr 17, 2025 | clinicaltrials |
Data updated 24 days agoSource updated May 16, 2025source: clinicaltrials